Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Shenzhen Forward Pharmaceuticals Co. Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units. REILLY, SOPHIA JANE is the busiest examiner, with 1 pending action.
The matching counts show a separate examiner and technical-unit path for each pending action. Prosecution management should therefore emphasize coordinated docketing and consistent scientific terminology rather than relying on a single examiner strategy. The REILLY matter is one individual assignment, and the profile does not indicate concentration in any one art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002578 | Salts of Compound and Pharmaceutical Compositions Containing the Same | HEITMEIER, KENDALL NICOLE | 23d |
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | — |
| 18259871 | Anti-FGFR2 Antibody and Use Thereof | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1641 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | 1627 | §102§103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18259871 | Anti-FGFR2 Antibody and Use Thereof | PETERS, ALEC JON | 1641 | §112DP | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18002578 | Salts of Compound and Pharmaceutical Compositions Containing the Same | HEITMEIER, KENDALL NICOLE | 1621 | §103Other | Final Rejection | 23d | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Forward Pharmaceuticals Co. Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Sophia Jane Reilly has the most, with 1 of Shenzhen Forward Pharmaceuticals Co. Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
